Mitsubishi Tanabe Pharma Corp.: PharmaVitae Profile

Date: April 1, 2011
Pages: 63
Price:
US$ 5,700.00
Publisher: Datamonitor
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MEEE97CE444EN
Leaflet:

Download PDF Leaflet

Mitsubishi Tanabe Pharma Corp.: PharmaVitae Profile
Introduction

This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits
  • Gain insight into Mitsubishi Tanabe's strategic outlook across the next 6 years
  • Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights

This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Your key questions answered
  • Benchmark Mitsubishi Tanabe's performance against key rivals in the prescription pharmaceutical sector
  • See how the launch of pipeline products will generate modest growth and offset expiring product declines for the company

Executive Summary
  Key findings
  Prescription pharmaceutical sales and growth rate analysis, 2003–15
  Operating costs and profit analysis
  Mitsubishi Tanabe: PharmaVitae forecasts at a glance
  Strategic insight
    2007: Tanabe and Mitsubishi merge amid a wave of Japanese consolidation
    2009–15: greater scale but slow growth
  SWOT analysis
    Strengths
    Weaknesses
    Opportunities
    Threats

ABOUT THIS PROFILE

  PharmaVitae Explorer database
  Chapter structure
    Quarterly update
    Company introduction
    Company sales
    Company financials
    Key products and competitors
  Data sourcing
    Analyst consensus

QUARTERLY UPDATE

  Latest prescription pharma product news
    Q2 2010
    Q1 2010
    Q4 2009
    Q3 2009
  Latest corporate news
    Q2 2010
    Q1 2010
    Q3 2009
  Future product milestones

COMPANY INTRODUCTION

  Key findings
  Background
  M&A history
    Merger of Mitsubishi Pharma and Tanabe Seiyaku
    M&A history: Mitsubishi Pharma
    M&A history: Tanabe Seiyaku
    M&A strategy
  Current corporate structure
    Pharmaceuticals segment
    Other business segment

COMPANY SALES

  Key findings
  Prescription pharmaceutical sales and growth rate analysis, 2003–15
  Product analysis
    Product analysis, 2003–09
    Product analysis, 2009–15
  Therapy area analysis
  Geographic analysis
  Launch/core/expiry analysis
    Explanation of launch/core/expiry analysis
    Launch analysis, 2009–15
    Core analysis, 2009–15
    Expiry analysis, 2009–15
    Launch/core/expiry configuration, 2009–15
  Molecule type analysis
  Externalization analysis

COMPANY FINANCIALS

  Key findings
  Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
  Operating costs and profit analysis
    Operating costs and profit analysis, 2003–09
    Operating cost ratio and profit margin analysis, 2003–09
    Operating cost ratio and profit margin analysis, 2009–15
    Operating costs and profit analysis, 2009–15

APPENDIX

  References

Ask Your Question

Mitsubishi Tanabe Pharma Corp.: PharmaVitae Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: